Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Evolus, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
About This Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of Evolus, Inc. (NASDAQ: EOLS).
On October 2, 2026, Evolus, Inc. revealed that it had received a warning letter from the U.S. Food and Drug Administration (FDA) concerning allegedly false or misleading Instagram promotions of its wrinkle treatment, Jeuveau. According to the FDA, the Company’s promotional materials minimized important safety information while making claims that Jeuveau could deliver “complete results.” Following this news, Evolus’s stock price declined approximately 7.15% on October 2, 2026.
What We Are Investigating
- Whether Evolus, Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- Whether Evolus, Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
What Investors Should Do
EOLS — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”